"HIV treatment is associated with increases in the amino acid homocysteine, which may help explain the higher rates of arterial disease seen in people living with HIV receiving antiretroviral (ARV) therapy compared with those not infected with the virus, according to a small Mexican study published online ahead of print by the Journal of Acquired Immune Deficiency Syndromes (JAIDS). ...
"Going forward, the study authors said, therapies known to lower homocysteine should be explored. “For example, some patients may benefit from betaine (trimethylglycine) or choline (in the form of phosphatidylcholine),” they write. “These therapies have been used in the general population with variable degrees of success."
Read more in POZ, March 29, 2010.
Note: Both betaine and phosphatidylcholine are readily available as supplements.
0 comments:
Post a Comment